Table 1 Detailed patient overview
Patient no. | Gender | Age | Number of lesions | Number of irradiated lesions | Max. diameter [cm] | Pre-treatment in-loco | Histology | LC [months] | OS [months] | Response | Comorbidities | Comment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | F | 78 | 1 | 1 | 4.5 | none | yes | 9.4 | 10.7 | PR | History of breast cancer and stroke, diabetes mell. type II | PROMETHEUS |
2 | M | 63 | 1 | 1 | 2.0 | Yes, RFA in loco | no, local relapse, CT + MRI | 11.3 | 11.3 | SD | History of metastasized seminoma, AL-amyloidosis type lambda, MALT-lymphoma of the lung, cardiomyopathy, coronary heart disease, diabetes mell. Type II | |
3 | M | 67 | 1 | 1 | 3.3 | none | No, CT + MRI | 11.8 | 12.7 | PR | diabetes mell. type II, myasthenia gravis, congestive heart failure | |
4 | F | 78 | 2 | 2 | 3.7 and 0.9 | none | Yes | 11.9 | 11.9 | PR | diabetes mell. type II, COPD II° | |
5 | M | 53 | multiple | 1 | 4.0 | none | Yes | 3.4 | 3.4 | SD | History of renal cell carcinoma, cardiomyopathy, coronary heart disease, diabetes mell. type II | Sorafenib and liver transplantation after RT |
6 | F | 71 | 2 | 1 | 3.4 | Yes, PEI and TACE | no, local relapse, CT + MRI | 2.7 | 4.0* | SD | diabetes mell. type II, history of pituitary adenoma, hemochromatosis | Received TACE for 2nd lesion, PROMETHEUS |